Oxford Biomedica Regulatory News (OXB)

OXFORD BIOMEDICA PLC

CIRCULAR & GENERAL MEETING NOTIFICATION

Oxford UK - 11 December 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB) gives notice that, further to the announcement on 19 November 2013 of the proposed up to £5 million secured loan facility agreement with its largest shareholder, the Vulpes Life Sciences Fund, a circular to shareholders was posted yesterday and is available on the "Investors" section of the Company's website at www.oxfordbiomedica.co.uk.

A copy of this document has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.hemscott.com/nsm.do.

Oxford BioMedica plc also announces that a General Meeting will be held on Monday 6 January 2014 at 10.00 a.m. at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH.

- Ends -

Notes to editors

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.